Dr Sujith Samarasinghe
Overview
Dr Sujith Samarasinghe completed his medical training at Imperial School of Medicine, London in 1998. He did his paediatric haematology training in Great Ormond Street Hospital (GOSH) and University College Hospital, London. He was awarded a PhD in 2010 from University College London in the field of immunotherapy for leukaemia. In 2011, he was appointed as a consultant haematologist in Newcastle but returned to GOSH in 2014. His areas of expertise include childhood leukaemia and aplastic anaemia. He is a clinical trial coordinator for the national UK Acute lymphoblastic leukaemia trial, 2011, the national lead for childhood aplastic anaemia and supportive care and a coinvestigator on two CAR T-cell studies in childhood leukaemia.
Credentials
- Bone marrow failure
- Aplastic anaemia
- Childhood Leukaemia
- BSc
- MBBS
- MRCPCH
- FRCPath
- PhD
Dr Sujith Samarasinghe completed his medical training at Imperial School of Medicine, London in 1998. He did his paediatric haematology training in Great Ormond Street Hospital (GOSH) and University College Hospital, London. He was awarded a PhD in 2010 from University College London in the field of immunotherapy for leukaemia. In 2011, he was appointed as a consultant haematologist in Newcastle but returned to GOSH in 2014. His areas of expertise include childhood leukaemia and aplastic anaemia. He is a clinical trial coordinator for the national UK Acute lymphoblastic leukaemia trial, 2011, and the national lead for childhood aplastic anaemia He is lead investigator for a European Study in blinatumomab in Down Syndrome ALL and Co-Chief Investigator Elect for the next ALL Together 2 Trial, a consortium of European countries treating paediatric and young adult acute lymphoblastic leukaemia. His main area of interest is front line immunotherapy for childhood ALL.
News & Publications
Wolthers BO, Frandsen TL, Baruchel A, Attarbaschi A, Barzilai S, Colombini A, Escherich G, Grell K, Inaba H, Kovacs G, Liang DC, Mateos M, Mondelaers V, Möricke A, Ociepa T, Samarasinghe S, Silverman LB, van der Sluis IM, Stanulla M,
Vrooman LM, Yano M, Zapotocka E, Schmiegelow K; Ponte di Legno Toxicity Working Group. Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study. Lancet Oncol. 2017 Sep;18(9):1238-1248.
Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, Ghorashian S, Pinner D, Ahsan G, Gilmour K, Lucchini G, Inglott S, Mifsud W, Chiesa R, Peggs KS, Chan L, Farzeneh F, Thrasher AJ, Vora
A, Pule M, Veys P. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017 Jan 25;9(374)
O'Connor D, Moorman AV, Wade R, Hancock J, Tan RM, Bartram J, Moppett J, Schwab C, Patrick K, Harrison CJ, Hough R, Goulden N, Vora A, Samarasinghe S. Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia. J Clin Oncol. 2017 Feb 20;35(6):660-667
Alexander S, Pole JD, Gibson P, Lee M, Hesser T, Chi SN, Dvorak CC, Fisher B, Hasle H, Kanerva J, Möricke A, Phillips B, Raetz E, Rodriguez-Galindo C, Samarasinghe S, Schmiegelow K, Tissing W, Lehrnbecher T, Sung L; International
Pediatric Oncology Mortality Classification Group. Classification of treatment-related mortality in children with cancer: a systematic assessment. Lancet Oncol. 2015 Dec;16(16):e604-10.
Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, Hillmen P, Ireland R, Kulasekararaj A, Mufti G, Snowden JA, Samarasinghe S, Wood A, Marsh JC; British Society for Standards in Haematology. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016 Jan;172(2):187-207
O'Connor D, Bate J, Wade R, Clack R, Dhir S, Hough R, Vora A, Goulden N, Samarasinghe S. Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003. Blood. 2014 Aug14;124(7):1056-61.
Refer your child to Dr Sujith Samarasinghe
Use the form below to refer your child for treatment. A member of our team will be in touch within 2 working days.
Mandatory fields
